At the HL7 Genomics Conference, a FHIR Genomics developer unveiled the Consortium for Agile Genomics to promote implementation of the nascent standard.

At the AGBT conference this week, the DNA synthesis discussed the new capture products and its overall business.

The company intends to use the funds to advance its Cota Nodal Address disease classification system and other platforms.

The updated recommendations discuss testing for DNA repair gene mutations, MSI-H, and dMMR, as well as germline testing and counseling.

London-based LGC said that the acquisition increases its exposure to the next-generation sequencing and gene editing markets.

At AGBT, researchers described applications for rapid pathogen ID; evaluating DNA, RNA, and gene expression in one assay; and understanding tumor heterogeneity.

The company plans to launch a single-cell CNV assay, a single cell ATAC-seq assay, and a single-cell feature barcoding assay later this year.

The increased revenues were due primarily to cardiac immunoassay sales from the newly acquired Triage and BNP businesses as well as increased sales of rapid immunoassay products.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.

This application note demonstrates that:

• The new Applied Biosystems SeqStudio Genetic Analyzer generates high-quality data from multiplex ligation–dependent probe amplification (MLPA) assays developed by MRC-Holland.

• The SeqStudio Genetic Analyzer provides fast and efficient results; each run cycle accommodates 4 MLPA reaction samples and can be completed within 45 min.

Jan
10
Sponsored by
Biognosys

Protein concentrations are determined by the levels of their coding mRNAs, by their translation rates, and by protein turnover. However, how much does each of these processes contribute to observed protein levels? Does a weak correlation of protein and mRNA levels indicate poor quality of the data? Or does it imply that post-transcriptional processes substantially contribute fine-tuning protein levels? The webinar will address these and related questions.